Vtv Therapeutics Stock Buy Hold or Sell Recommendation
| VTVT Stock | USD 25.50 0.52 2.08% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding vTv Therapeutics is 'Strong Sell'. Macroaxis provides VTv Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding VTVT positions. The advice algorithm takes into account all of VTv Therapeutics' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting VTv Therapeutics' buy or sell advice are summarized below:
Real Value 18.3 | Target Price 3 | Hype Value 24.98 | Market Value 25.5 | Naive Value 25.51 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell vTv Therapeutics given historical horizon and risk tolerance towards VTv Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for vTv Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
VTv |
Execute VTv Therapeutics Buy or Sell Advice
The VTv recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on vTv Therapeutics. Macroaxis does not own or have any residual interests in vTv Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute VTv Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Good | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
VTv Therapeutics Trading Alerts and Improvement Suggestions
| vTv Therapeutics is way too risky over 90 days horizon | |
| vTv Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 9 K. Net Loss for the year was (20.25 M) with loss before overhead, payroll, taxes, and interest of (9.93 M). | |
| vTv Therapeutics currently holds about 17.95 M in cash with (18.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22. | |
| Roughly 55.0% of the company outstanding shares are owned by insiders | |
| Latest headline from news.google.com: vTv Therapeutics Stock Price Passes Above Fifty Day Moving Average of 18.21 - Defense World |
VTv Therapeutics Returns Distribution Density
The distribution of VTv Therapeutics' historical returns is an attempt to chart the uncertainty of VTv Therapeutics' future price movements. The chart of the probability distribution of VTv Therapeutics daily returns describes the distribution of returns around its average expected value. We use vTv Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of VTv Therapeutics returns is essential to provide solid investment advice for VTv Therapeutics.
| Mean Return | 2.33 | Value At Risk | -8.23 | Potential Upside | 14.90 | Standard Deviation | 13.63 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of VTv Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
VTv Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as VTv Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading vTv Therapeutics backward and forwards among themselves. VTv Therapeutics' institutional investor refers to the entity that pools money to purchase VTv Therapeutics' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Cornerstone Planning Group Llc | 2023-12-31 | 19.0 | Sunbelt Securities | 2023-12-31 | 15.0 | Jpmorgan Chase & Co | 2023-12-31 | 1.0 | Bank Of America Corp | 2023-12-31 | 1.0 | State Street Corporation | 2023-12-31 | 0.0 | Susquehanna International Group, Llp | 2023-12-31 | 0.0 | Northern Trust Corp | 2023-12-31 | 0.0 | Millennium Management Llc | 2023-12-31 | 0.0 | Bnp Paribas Arbitrage, Sa | 2023-12-31 | 0.0 | Pathstone Family Office, Llc | 2023-09-30 | 242.9 K | Samsara Biocapital, Llc | 2023-12-31 | 40.9 K |
VTv Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 94K | 1.5M | 7.7M | (1.3M) | (2.7M) | (2.5M) | |
| Free Cash Flow | (23.1M) | (18M) | (19.3M) | (16.0M) | (18.5M) | (19.4M) | |
| Depreciation | 39K | 94K | 89K | 92K | 90K | 85.5K | |
| Other Non Cash Items | 532K | 380K | (4.1M) | 2.3M | (1.3M) | (1.3M) | |
| Net Income | (21.9M) | (12.8M) | (17.7M) | (25.1M) | (20.3M) | (21.3M) | |
| End Period Cash Flow | 4.3M | 5.7M | 13.4M | 12.1M | 9.4M | 15.0M | |
| Net Borrowings | (10.1M) | (5.0M) | 172K | (32K) | (28.8K) | (27.4K) | |
| Change To Netincome | 1.2M | 1.0M | (6.4M) | 4.5M | 5.2M | 5.4M | |
| Change Receivables | 8M | (5K) | (153K) | (116K) | (133.4K) | (126.7K) | |
| Investments | 7K | 242K | (68K) | (21K) | 4.4M | 4.6M |
VTv Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to VTv Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that VTv Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a VTv stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 2.22 | |
β | Beta against NYSE Composite | 1.22 | |
σ | Overall volatility | 13.72 | |
Ir | Information ratio | 0.16 |
VTv Therapeutics Volatility Alert
vTv Therapeutics is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure VTv Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact VTv Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.VTv Therapeutics Fundamentals Vs Peers
Comparing VTv Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze VTv Therapeutics' direct or indirect competition across all of the common fundamentals between VTv Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as VTv Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of VTv Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing VTv Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare VTv Therapeutics to competition |
| Fundamentals | VTv Therapeutics | Peer Average |
| Return On Equity | -49.78 | -0.31 |
| Return On Asset | -0.72 | -0.14 |
| Current Valuation | 57.91 M | 16.62 B |
| Shares Outstanding | 2.43 M | 571.82 M |
| Shares Owned By Insiders | 54.68 % | 10.09 % |
| Shares Owned By Institutions | 16.05 % | 39.21 % |
| Number Of Shares Shorted | 32.24 K | 4.71 M |
| Price To Earning | (4.19) X | 28.72 X |
| Price To Sales | 3,631 X | 11.42 X |
| Revenue | 9 K | 9.43 B |
| Gross Profit | (9.93 M) | 27.38 B |
| EBITDA | (25.41 M) | 3.9 B |
| Net Income | (20.25 M) | 570.98 M |
| Cash And Equivalents | 17.95 M | 2.7 B |
| Cash Per Share | 0.22 X | 5.01 X |
| Total Debt | 529 K | 5.32 B |
| Debt To Equity | 0.08 % | 48.70 % |
| Current Ratio | 3.12 X | 2.16 X |
| Book Value Per Share | (11.84) X | 1.93 K |
| Cash Flow From Operations | (18.52 M) | 971.22 M |
| Short Ratio | 0.18 X | 4.00 X |
| Earnings Per Share | (9.71) X | 3.12 X |
| Target Price | 2.0 | |
| Number Of Employees | 16 | 18.84 K |
| Beta | 0.58 | -0.15 |
| Market Capitalization | 58.4 M | 19.03 B |
| Total Asset | 11.02 M | 29.47 B |
| Retained Earnings | (281.04 M) | 9.33 B |
| Working Capital | 38 K | 1.48 B |
| Current Asset | 52.12 M | 9.34 B |
| Current Liabilities | 10.58 M | 7.9 B |
| Net Asset | 11.02 M |
Note: Acquisition by John Fry of 205 shares of VTv Therapeutics at 0.8262 subject to Rule 16b-3 [view details]
VTv Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as VTv . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About VTv Therapeutics Buy or Sell Advice
When is the right time to buy or sell vTv Therapeutics? Buying financial instruments such as VTv Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 932K | 716K | 529K | 502.6K | Total Assets | 25.5M | 33.2M | 11.0M | 10.5M |
Use Investing Ideas to Build Portfolios
In addition to having VTv Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investing Thematic Idea Now
Investing
Companies involved in money management and investment banking services. The Investing theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investing Theme or any other thematic opportunities.
| View All Next | Launch |
Check out VTv Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy VTv Stock please use our How to Invest in VTv Therapeutics guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for VTv Stock analysis
When running VTv Therapeutics' price analysis, check to measure VTv Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VTv Therapeutics is operating at the current time. Most of VTv Therapeutics' value examination focuses on studying past and present price action to predict the probability of VTv Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VTv Therapeutics' price. Additionally, you may evaluate how the addition of VTv Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |
Is VTv Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VTv Therapeutics. If investors know VTv will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VTv Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.71) | Revenue Per Share 0.004 | Return On Assets (0.72) | Return On Equity (49.78) |
The market value of vTv Therapeutics is measured differently than its book value, which is the value of VTv that is recorded on the company's balance sheet. Investors also form their own opinion of VTv Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VTv Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VTv Therapeutics' market value can be influenced by many factors that don't directly affect VTv Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VTv Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VTv Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VTv Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.